2023
Computational Prediction of the Interaction of Ivermectin with Fibrinogen
Vottero P, Tavernini S, Santin A, Scheim D, Tuszynski J, Aminpour M. Computational Prediction of the Interaction of Ivermectin with Fibrinogen. International Journal Of Molecular Sciences 2023, 24: 11449. PMID: 37511206, PMCID: PMC10380762, DOI: 10.3390/ijms241411449.Peer-Reviewed Original ResearchConceptsSpike proteinSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Acute COVID-19Coagulation factor fibrinogenSyndrome coronavirus 2Interactions of ivermectinBlood coagulation factor fibrinogenSARS-CoV-2 spike proteinAbnormal blood clotsAntiparasitic drug ivermectinLong COVIDFactors fibrinogenCoronavirus 2Proinflammatory activityClot propertiesPathologic thrombosisClot formationBlood clotsDrug ivermectinIvermectinFibrinogen peptidesFibrin clotsCOVID-19
2022
High Altitude Induced Thrombosis: Challenges and Recent Advancements in Pathogenesis and Management
Tyagi T, Jain K. High Altitude Induced Thrombosis: Challenges and Recent Advancements in Pathogenesis and Management. 2022, 85-101. DOI: 10.1007/978-981-19-1008-1_6.ChaptersMolecular pathogenesisAvailable treatment optionsBlood clot formationPulmonary embolismVenous thrombosisTreatment optionsClinical managementRisk factorsAnimal studiesHigh-altitude hypoxic environmentClot formationSerious disorderPathogenesisThrombosisHypoxic environmentVTEDisordersNumber of humanEmbolism
2021
Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure
Stravitz RT, Fontana RJ, Meinzer C, Durkalski‐Mauldin V, Hanje AJ, Olson J, Koch D, Hamid B, Schilsky M, McGuire B, Ganger D, Liou I, Karvellas CJ, Rule JA, Lisman T, Clasen K, Reuben A, Cripps M, Lee WM, Group A. Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure. Hepatology 2021, 74: 937-949. PMID: 33636020, PMCID: PMC10668528, DOI: 10.1002/hep.31767.Peer-Reviewed Original ResearchConceptsALI/ALFROTEM parametersRotational thromboelastometryDisease severityAcute liver injury/failureAbnormal hemostatic profileSevere systemic complicationsAcute liver injuryBleeding eventsBleeding riskLiver transplantationSystemic complicationsHemostatic failureLiver injuryIllness severityNative liverAbnormal hemostasisHemostatic profileStudy groupHigh incidencePatientsNormal rangeLaboratory evidenceClot formationClot stability
2020
Hematologic Disorders
Amin H, Schindler J. Hematologic Disorders. 2020, 193-201. DOI: 10.1007/978-3-030-52552-1_15.ChaptersHematological conditionsStrong family historyHypercoagulable panelStroke therapeuticsIschemic strokeSecondary preventionStroke neurologistsYounger patientsAcute treatmentHypercoagulable conditionsHematologic disordersFamily historyHematological disordersClot formationCoagulation cascadeStrokePatientsDisordersNeurologistsPrevention
2019
Induction of Secretagogue Independent Gastric Acid Secretion via a Novel Aspirin-Activated Pathway
Kitay AM, Ferstl FS, Link A, Geibel JP. Induction of Secretagogue Independent Gastric Acid Secretion via a Novel Aspirin-Activated Pathway. Frontiers In Physiology 2019, 10: 1264. PMID: 31649553, PMCID: PMC6795678, DOI: 10.3389/fphys.2019.01264.Peer-Reviewed Original ResearchGastric acid secretionNon-selective NOS inhibitor L-NAMENOS inhibitor L-NAMEInhibitor L-NAMEAcid secretionL-NAMESoluble guanylyl cyclase inhibitor 1HGuanylyl cyclase inhibitor 1HIncreases nitric oxide productionUsage of aspirinGastric glandsPH-sensitive dye BCECF-AMNitric oxide productionVariety of cancersNovel secretagogueBlood clot formationAspirin exposureChronic conditionsMucosal barrierRepetitive dosesUlcer formationAspirin consumptionBasolateral exposureAspirinClot formation
2016
Hematologic Disorders
Amin H, Schindler J. Hematologic Disorders. 2016, 147-154. DOI: 10.1007/978-3-319-39605-7_15.Peer-Reviewed Original ResearchHematological conditionsStrong family historyHypercoagulable panelStroke therapeuticsIschemic strokeSecondary preventionStroke neurologistsYounger patientsAcute treatmentHypercoagulable conditionsHematologic disordersFamily historyHematological disordersClot formationCoagulation cascadeStrokePatientsDisordersNeurologistsPrevention
2013
Adjunctive Pharmacology for Coronary Intervention
Faheem O, Forrest J. Adjunctive Pharmacology for Coronary Intervention. 2013, 143-156. DOI: 10.1007/978-1-4471-4528-8_11.Peer-Reviewed Original ResearchST-elevation myocardial infarctionStable coronary plaquesAcute coronary syndromeOral antiplatelet agentsElevation myocardial infarctionArterial thrombus formationAdjunctive pharmacologyRoutine PCIVon Willebrand factorCoronary syndromeCoronary interventionAntiplatelet agentsCoronary plaquesMyocardial infarctionThromboxane A2Plaque ruptureThrombus formationPlatelet activationClot formationPlatelet aggregationWillebrand factorPlateletsPivotal rolePlatelet adhesionInfarction
2010
Intravenous (IV) Thrombolysis
Nogueira R, Schwamm L. Intravenous (IV) Thrombolysis. 2010, 221-243. DOI: 10.1007/978-3-642-12751-9_11.Peer-Reviewed Original Research
2006
Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH
PAIS SA, NATHWANI RA, DHAR V, NOWAIN A, LAINE L. Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH. Alimentary Pharmacology & Therapeutics 2006, 23: 1607-1613. PMID: 16696810, DOI: 10.1111/j.1365-2036.2006.02933.x.Peer-Reviewed Original ResearchConceptsProton pump inhibitorsPump inhibitorsOral proton pump inhibitorsDoses of lansoprazoleFrequent oral dosingLansoprazole plasma concentrationHelicobacter pylori statusCYP2C19 statusOral lansoprazolePylori statusOvernight fastOral dosingPlasma concentrationsFrequent dosingHealthy volunteersClot formationTime pointsLansoprazoleMean proportionDosingInhibitorsSubjectsStatusPatientsPeriod
1996
Prostaglandin E2 Stimulates a Ca2+-dependent K+ Channel in Human Erythrocytes and Alters Cell Volume and Filterability*
Li Q, Jungmann V, Kiyatkin A, Low P. Prostaglandin E2 Stimulates a Ca2+-dependent K+ Channel in Human Erythrocytes and Alters Cell Volume and Filterability*. Journal Of Biological Chemistry 1996, 271: 18651-18656. PMID: 8702518, DOI: 10.1074/jbc.271.31.18651.Peer-Reviewed Original ResearchConceptsProstaglandin E2Red blood cellsRelease of PGE2Efflux pathwayGardos channel inhibitorGardos channel activationM. Prostaglandin E2PGE2 treatmentIntact red blood cellsHuman erythrocytesMean cell volumeChannel inhibitorsClot formationEffects of metabolitesCell shrinkageGardos channelHuman red blood cellsNa/K/2Cl cotransportBlood cellsOsmotic fragilityChannel activationRed cellsPossible involvementPlateletsCell volume
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply